After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

The patent infringement lawsuit between Amgen (Thousand Oaks, CA) and Transkaryotic Therapies (TKT; Cambridge, MA), to determine which has the US right to exclude others from “making ...

Amgen's stock price remains nearly unchanged over 1.5 years, but its valuation may now be more reasonable or even a bargain. Despite high debt from the Horizon Therapeutics acquisition, Amgen ...